Volume 89, Issue 3, Pages (March 2016)

Slides:

Advertisements

Similar presentations

Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease D.M. Charytan,

Advertisements

Reduced renal function in patients with simple renal cysts

Treatment options for HUS secondary to Escherichia coli O157:H7

Lakhmir S. Chawla, Paul L. Kimmel Kidney International

Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease D.M. Charytan,

Volume 152, Issue 2, Pages (August 2017)

Diagnosis and Management of Chronic Kidney Disease

Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle

Section 2: AKI Definition

Volume 94, Issue 4, Pages (October 2018)

Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH Sandra Habbig, MD, Carsten Bergmann, MD,

Volume 87, Issue 5, Pages (May 2015)

Prehypertension and chronic kidney disease: the ox or the plow?

Recent outbreak of hemolytic uremic syndrome in Germany

Volume 80, Issue 1, Pages (July 2011)

Volume 88, Issue 2, Pages (August 2015)

Volume 66, Issue 1, Pages (July 2004)

Volume 54, Issue 2, Pages (August 1998)

Volume 59, Issue 1, Pages (January 2001)

Erratum American Journal of Kidney Diseases

Volume 77, Issue 8, Pages (April 2010)

Volume 79, Issue 12, Pages (June 2011)

Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian, Yan Yan, Ziyad Al-Aly

Treatment options for HUS secondary to Escherichia coli O157:H7

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial Fadi Fakhouri, MD,

Volume 77, Issue 1, Pages 5-6 (January 2010)

Piero Ruggenenti, Marina Noris, Giuseppe Remuzzi Kidney International

How to interpret the eGFR in patients with small body surface area

Volume 79, Issue 5, Pages (March 2011)

Ananda Chapagain, Hamish Dobbie, Michael Sheaff, Muhammad M. Yaqoob

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Volume 89, Issue 5, Pages (May 2016)

Bariatric surgery is associated with improvement in kidney outcomes

Volume 87, Issue 2, Pages (February 2015)

Quiz Page July 2012 American Journal of Kidney Diseases

U-shaped effect of eGFR and mortality

Volume 76, Issue 10, Pages (November 2009)

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease Joan C. Lo, Glenn M. Chertow, Alan S. Go, Chi-Yuan.

Blood pressure targets in hemodialysis patients

Volume 85, Issue 3, Pages (March 2014)

Volume 90, Issue 5, Pages (November 2016)

Volume 81, Issue 6, Pages (March 2012)

Volume 76, Issue 3, Pages (August 2009)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Methods for guideline development

Volume 93, Issue 1, Pages (January 2018)

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Reduced renal function in patients with simple renal cysts

Simvastatin in nephrotic syndrome

Volume 71, Issue 4, Pages (February 2007)

Volume 85, Issue 5, Pages (May 2014)

Douglas G Matsell, Colin T White Kidney International

Volume 54, Issue 4, Pages (October 1998)

Volume 74, Issue 9, Pages (November 2008)

Volume 79, Issue 4, Pages (February 2011)

Volume 63, Issue 2, Pages (February 2003)

Blood lead and chronic kidney disease in the general United States population: Results from NHANES III Paul Muntner, Jiang He, Suma Vupputuri, Josef.

Volume 80, Issue 10, Pages (November 2011)

Volume 89, Issue 5, Pages (May 2016)

Volume 66, Issue 3, Pages (September 2004)

Volume 62, Issue 6, Pages (December 2002)

Renal prognosis of toxigenic Escherichia coli infection

Adiponectin: good, bad, or just plain ugly?

The International Pediatric Peritonitis Registry: Starting to walk

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Volume 57, Issue 4, Pages (April 2000)

Volume 73, Issue 11, Pages (June 2008)

A diagnostic algorithm for the investigation and management of a patient presenting with thrombotic microangiopathy. A diagnostic algorithm for the investigation.

Presentation transcript:

Volume 89, Issue 3, Pages 701-711 (March 2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I. Al-Akash, Jonathan Evans, Paul Henning, Kenneth V. Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole C.A.J. van de Kar, Johan Vande Walle, Masayo Ogawa, Camille L. Bedrosian, Christoph Licht Kidney International Volume 89, Issue 3, Pages 701-711 (March 2016) DOI: 10.1016/j.kint.2015.11.026 Copyright © 2016 International Society of Nephrology Terms and Conditions

Figure 1 Patient disposition. aLDH ≥ 1.5 × ULN; hemoglobin ≤ LLN; fragmented red blood cells with a negative Coombs test result. bOne patient had a positive test for STEC infection, 1 had a normalized platelet count; 2 had a final diagnosis that was not aHUS, 1 had unspecified reasons. aHUS, atypical hemolytic uremic syndrome; LDH, lactate dehydrogenase; LLN, lower limit of normal; SAE, serious adverse event; SCr, serum creatinine; STEC, Shiga-like toxin-producing Escherichia coli; ULN, upper limit of normal. Kidney International 2016 89, 701-711DOI: (10.1016/j.kint.2015.11.026) Copyright © 2016 International Society of Nephrology Terms and Conditions

Figure 2 Improvement in platelet count over 27 weeks of eculizumab treatment. N values <5 were not included. Bars represent SEM. Arrows denote administration of eculizumab. Kidney International 2016 89, 701-711DOI: (10.1016/j.kint.2015.11.026) Copyright © 2016 International Society of Nephrology Terms and Conditions

Figure 3 Improvement in platelet count over 27 weeks of eculizumab treatment in individual patients. Kidney International 2016 89, 701-711DOI: (10.1016/j.kint.2015.11.026) Copyright © 2016 International Society of Nephrology Terms and Conditions

Figure 4 Improvement in estimated glomerular filtration rate (eGFR) over 27 weeks of eculizumab treatment. N values <5 were not included. Bars represent SEM. Arrows denote administration of eculizumab. Kidney International 2016 89, 701-711DOI: (10.1016/j.kint.2015.11.026) Copyright © 2016 International Society of Nephrology Terms and Conditions

Figure 5 Improvement in estimated glomerular filtration rate (eGFR) over 27 weeks of eculizumab treatment in individual patients. Kidney International 2016 89, 701-711DOI: (10.1016/j.kint.2015.11.026) Copyright © 2016 International Society of Nephrology Terms and Conditions